These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 36812883)

  • 1. Benefits and Harms of Continuous Intravenous Inotropic Support as Palliative Therapy: A Single-Institution, Retrospective Analysis.
    Rao A; Maini M; Anderson KM; Crowell NA; Gholami SS; Foley Lgsw C; Violanti D; Singh M; Sheikh FH; Najjar SS; Groninger H
    Am J Hosp Palliat Care; 2024 Jan; 41(1):50-55. PubMed ID: 36812883
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chronic Intravenous Inotropic Support as Palliative Therapy and Bridge Therapy for Patients With Advanced Heart Failure: A Single-Center Experience.
    Rao A; Anderson KM; Mohammed S; Hofmeyer M; Gholami SS; Sheikh FH; Rodrigo ME; Crowell NA; Javed H; Gupta S; Hajouli S; Stewart DE; Hamad A; Najjar SS; Groninger H
    J Card Fail; 2021 Sep; 27(9):974-980. PubMed ID: 34153459
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disease-State Understanding and Experience of Patients Receiving Continuous Intravenous Inotropic Support as Palliative Therapy: A Multicenter Survey.
    Maini M; Anderson KM; Seplowe M; Crowell NA; Pitcher C; Scally R; Weintraub WS; Najjar SS; Groninger H; Rao A
    J Palliat Med; 2024 Apr; ():. PubMed ID: 38564223
    [No Abstract]   [Full Text] [Related]  

  • 4. Bridge to nowhere: A retrospective single-center study on patients using chronic intravenous inotropic support as bridge therapy who do not receive surgical therapy.
    Rao A; Singh M; Maini M; Anderson KM; Crowell NA; Henderson PR; Gholami SS; Sheikh FH; Najjar SS; Groninger H
    Front Cardiovasc Med; 2022; 9():918146. PubMed ID: 36110411
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Continuous Intravenous Inotropic Support for Advanced Heart Failure: Palliative Considerations.
    McPherson A; Nguyen C; Groninger H; Anderson KM; Henderson P; Rao A
    J Pain Palliat Care Pharmacother; 2022 Mar; 36(1):59-67. PubMed ID: 35319327
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Need for hospice and palliative care services in patients with end-stage heart failure treated with intermittent infusion of inotropes.
    López-Candales AL; Carron C; Schwartz J
    Clin Cardiol; 2004 Jan; 27(1):23-8. PubMed ID: 14743852
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of intravenous home dobutamine in palliative end-stage heart failure on quality of life, heart failure hospitalization, and cost expenditure.
    Martens P; Vercammen J; Ceyssens W; Jacobs L; Luwel E; Van Aerde H; Potargent P; Renaers M; Dupont M; Mullens W
    ESC Heart Fail; 2018 Aug; 5(4):562-569. PubMed ID: 29341466
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ambulatory Inotrope Infusions in Advanced Heart Failure: A Systematic Review and Meta-Analysis.
    Nizamic T; Murad MH; Allen LA; McIlvennan CK; Wordingham SE; Matlock DD; Dunlay SM
    JACC Heart Fail; 2018 Sep; 6(9):757-767. PubMed ID: 30007556
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Care processes and clinical outcomes of continuous outpatient support with inotropes (COSI) in patients with refractory endstage heart failure.
    Hershberger RE; Nauman D; Walker TL; Dutton D; Burgess D
    J Card Fail; 2003 Jun; 9(3):180-7. PubMed ID: 12815567
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advanced heart failure patients supported with ambulatory inotropic therapy: What defines success of therapy?
    Grubb CS; Truby LK; Topkara VK; Bohnen MS; Yuzefpolskaya M; DeFilippis EM; Kleet A; Nakagawa S; Haythe JH; Axsom K; Colombo P; Takeda K; Uriel N; Sayer G; Garan H; Naka Y; Farr M
    Am Heart J; 2021 Sep; 239():11-18. PubMed ID: 33984317
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravenous continuous home inotropic therapy in advanced heart failure: Insights from an observational retrospective study.
    Gentile P; Masciocco G; Palazzini M; Tedeschi A; Ruzzenenti G; Conti N; D'Angelo L; Foti G; Perna E; Verde A; Ammirati E; Sinagra G; Oliva F; Garascia A
    Eur J Intern Med; 2023 Oct; 116():65-71. PubMed ID: 37393183
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Home inotropic therapy in advanced heart failure: cost analysis and clinical outcomes.
    Harjai KJ; Mehra MR; Ventura HO; Lapeyre YM; Murgo JP; Stapleton DD; Smart FW
    Chest; 1997 Nov; 112(5):1298-303. PubMed ID: 9367472
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment Initiation Patterns, Modifications, and Medication Adherence Among Newly Diagnosed Heart Failure Patients: A Retrospective Claims Database Analysis.
    Deschaseaux C; McSharry M; Hudson E; Agrawal R; Turner SJ
    J Manag Care Spec Pharm; 2016 May; 22(5):561-71. PubMed ID: 27123917
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Palliative inotrope therapy in advanced heart failure: organization and management].
    Gorni G; Correale M; Nodari S; Sinagra G
    G Ital Cardiol (Rome); 2020 Apr; 21(4):296-302. PubMed ID: 32202562
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiac resynchronization therapy in patients with end-stage inotrope-dependent class IV heart failure.
    Herweg B; Ilercil A; Cutro R; Dewhurst R; Krishnan S; Weston M; Barold SS
    Am J Cardiol; 2007 Jul; 100(1):90-3. PubMed ID: 17599447
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Palliative Inotrope Therapy: A Narrative Review.
    Chuzi S; Allen LA; Dunlay SM; Warraich HJ
    JAMA Cardiol; 2019 Aug; 4(8):815-822. PubMed ID: 31268467
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined oral positive inotropic and beta-blocker therapy for treatment of refractory class IV heart failure.
    Shakar SF; Abraham WT; Gilbert EM; Robertson AD; Lowes BD; Zisman LS; Ferguson DA; Bristow MR
    J Am Coll Cardiol; 1998 May; 31(6):1336-40. PubMed ID: 9581729
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Experience of morphine therapy for refractory dyspnea as palliative care in advanced heart failure patients.
    Kawaguchi J; Hamatani Y; Hirayama A; Nishimura K; Nakai E; Nakamura E; Miyata M; Kawano Y; Takada Y; Anchi Y; Funabashi S; Kuroda K; Azechi M; Takahama H; Anzai T; Yasuda S; Kitaoka H; Izumi C
    J Cardiol; 2020 Jun; 75(6):682-688. PubMed ID: 32061472
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial.
    Cuffe MS; Califf RM; Adams KF; Benza R; Bourge R; Colucci WS; Massie BM; O'Connor CM; Pina I; Quigg R; Silver MA; Gheorghiade M;
    JAMA; 2002 Mar; 287(12):1541-7. PubMed ID: 11911756
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low-dose oral enoximone enhances the ability to wean patients with ultra-advanced heart failure from intravenous inotropic support: results of the oral enoximone in intravenous inotrope-dependent subjects trial.
    Feldman AM; Oren RM; Abraham WT; Boehmer JP; Carson PE; Eichhorn E; Gilbert EM; Kao A; Leier CV; Lowes BD; Mathier MA; McGrew FA; Metra M; Zisman LS; Shakar SF; Krueger SK; Robertson AD; White BG; Gerber MJ; Wold GE; Bristow MR;
    Am Heart J; 2007 Nov; 154(5):861-9. PubMed ID: 17967591
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.